E Tsui, A Barnie, S Ross, R Parkes, B Zinman - Diabetes Care, 2001 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—This clinical trial enrolled 27 patients with type
1 diabetes. They were randomly assigned to CSII (n = 13) or MDI (n = 14)
treatment regimens. Glycemic control (HbA 1c level) was the primary outcome ... Cited by 79 - Related articles - BL Direct - All 10 versions
- ►diabetesjournals.org [PDF] H Hanaire-Broutin, V Melki, S Bessieres- … - Diabetes Care, 2000 - Am Diabetes Assoc According to the results of the Diabetes Control and Complications Trial (DCCT)
(1), intensive diabetes man- agement should be proposed for most type 1 diabetic
patients to prevent long-term com- plications. However, the ideal insulin ... Cited by 99 - Related articles - BL Direct - All 7 versions
JH DeVries, FJ Snoek, PJ Kostense, N … - Diabetes Care, 2002 - Am Diabetes Assoc RESULTS—As the drop-out rate after crossover was high (17 of 79 patients
[22%]), we analyzed the trial as a parallel clinical trial, using data of the
first half of the crossover phase only. At 16 weeks, mean HbA 1c was 0.84% ... Cited by 77 - Related articles - BL Direct - All 6 versions
[CITATION] Dutch Insulin Pump Study Group. A randomized trial of continuous subcutaneous insulin …
- ►bmj.com J Pickup, M Mattock, S Kerry - British Medical Journal, 2002 - bmj.com Continuous subcutaneous insulin infusion, often called insulin pump therapy, was
introduced in the 1970s as a way of achieving and maintaining strict control of
blood glucose concentrations in people with type 1 (insulin dependent) ... Cited by 256 - Related articles - BL Direct - All 10 versions
- ►diabetesjournals.org [PDF] R Retnakaran, B Zinman - Diabetes Care, 2005 - Am Diabetes Assoc Cardiac ventricles release B-type na- triuretic peptide (BNP) in response to
volume expansion and pressure overload; therefore, BNP concentration may be used
as a biochemical marker of cardiac failure (1). BNP levels are high in ... Cited by 95 - Related articles - BL Direct - All 8 versions
BW Bode, P Strange - Diabetes Care, 2001 - Am Diabetes Assoc OBJECTIVE— The purpose of this study was to compare the efficacy, safety, and
pump compatibility of insulin aspart (a rapid-acting insulin analog) and
buffered regular human insulin in patients with type 1 diabetes undergoing ... Cited by 83 - Related articles - BL Direct - All 13 versions
V Melki, E Renard, V Lassmann-Vague, S Boivin … - Diabetes care, 1998 - Am Diabetes Assoc T he Diabetes ControlandComplications Trial(DCCT) has clearlydemonstrated that
intensive diabetes management with the goal of maintaining near eugly- cemia
couldreduce the risk ofdevelopment and pro g ressionof ... Cited by 149 - Related articles - BL Direct - All 6 versions
R Renner, A Pfutzner, M Trautmann, O Harzer, … - Diabetes care, 1999 - Am Diabetes Assoc C ontinuous subcutaneous insulin infu- sion (CSII) with insulin pump devices is,
to date, the besttherapeuticoption to achieve near- no rmal blood glucose con- t
rol. Inpart icular, distinct subgroups of dia- betic patients may ... Cited by 149 - Related articles - BL Direct - All 6 versions
R Hoogma, AJM Spijker, M van Doorn-Scheele … - Medicine - njmonline.nl Research design and methods: The study included 49 patients (13 males, 36
females), aged 41.4 ± 11.3 years (mean ± SD) on CSII for >1 year and 79
patients (43 males, 36 females), aged 43.1 ± 14.8 years on MDII for >1 ... Cited by 16 - Related articles - View as HTML - All 6 versions
